← All trials
NCT00430768
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2006
- Primary completion
- Jan 1, 2015
- Completion date
- Jan 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 9
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of MassachusettsLead sponsor
- Alpha-1 FoundationCollaborator
- University of FloridaOverall official - principal investigator
- University of MassachusettsOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Applied Genetic Technologies CorpCollaborator
- University of FloridaCollaborator
- National Center for Research Resources (NCRR)Collaborator
- University of MassachusettsReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.